COLORADO SPRINGS, Colo., Nov. 17, 2014 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) will host an Analyst & Investor meeting in New York City on Thursday, December 4, 2014 beginning at 8:00 a.m. ET and concluding at 11:30 a.m. ET. The meeting will be hosted by Scott Drake, Spectranetics' President and CEO and will include a discussion of the multiple growth drivers within the Vascular Intervention and Lead Management businesses, with physician panels, and the Company's 2015 financial outlook.
All interested parties are invited to listen to the live webcast at http://www.spectranetics.com. An archived presentation of the webcast will be available on the Company's website for 30 days.
About Spectranetics
Spectranetics develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are sold in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.
Spectranetics recently acquired AngioScore, Inc., a leading developer, manufacturer and marketer of cardiovascular, specialty balloons.
The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee as well as the AngioSculpt® scoring balloon used in both peripheral and coronary procedures. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.
The Lead Management (LM) product line includes excimer laser sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.
For more information, visit www.spectranetics.com.
CONTACT: COMPANY CONTACT
The Spectranetics Corporation
Guy Childs, Chief Financial Officer
(719) 633-8333
INVESTOR CONTACTS
Westwicke Partners
Lynn Pieper
(415) 202-5678
lynn.pieper@westwicke.com
